Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients
Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients
复制标题
DOI：
10.3748/wjg.v21.i19.6018
复制
发表时间：
2015-05-21
影响因子：
4.3
通讯作者：
Gadaleta, Cosmo Damiano
中科院分区：
文献类型：
--
作者：
Ranieri, Girolamo;Ammendola, Michele;Gadaleta, Cosmo Damiano
目的：目的：探讨肝细胞癌（HCC）患者经肝动脉化疗栓塞（TACE）前后血清血管内皮生长因子（VEGF）和类胰蛋白酶（Tryptase）的变化。使用Quantikine人VEGF-酶联免疫吸附试验（ELISA）检查每个血清样品的VEGF水平，而使用Uni-CAP 100工具通过荧光酶免疫测定（FEIA）评估每个血清样品的类胰蛋白酶血清浓度。采用Student t检验评价TACE前后血清VEGF和类胰蛋白酶值的差异。Person's correlation被用来评估两个变量之间的关联程度。结果：肝癌患者TACE前VEGF水平和血清类胰蛋白酶的平均值和标准差（SD）分别为114.31 +/- 79.58 pg/mL和8.13 +/- 3.61 μ g/L。TACE后HCC患者的VEGF水平和血清类胰蛋白酶的平均水平和SD分别为238.14 ± 109.41 pg/mL和4.02 ± 3.03 μ g/L。治疗前后VEGF和类胰蛋白酶浓度的平均值变化有统计学意义（Wilcoxon-Mann-Whitney法分别为P < 0.000231和P < 0.00124）。TACE前后VEGF水平及类胰蛋白酶水平均呈显著相关（r = 0.68，P = 0.003; r = 0.84，P = 0.000）。结论：TACE后血清VEGF水平升高及类胰蛋白酶水平降低可能是TACE治疗后潜在的生物标志物变化。
AIM: To evaluate vascular endothelial growth factor (VEGF) and tryptase in hepatocellular cancer (HCC) before and after trans-arterial chemoembolization (TACE).METHODS: VEGF and tryptase serum concentrations were assessed from 71 unresectable HCC patients before and after hepatic TACE performed by binding DC-Beads (R) to doxorubicin. VEGF levels were examined for each serum sample using the Quantikine Human VEGF-enzyme-linked immuno-absorbent assay (ELISA), whereas tryptase serum concentrations were assessed for each serum sample by means of fluoro-enzyme immunoassay (FEIA) using the Uni-CAP100 tool. Differences between serum VEGF and tryptase values before and after TACE were evaluated using Student t test. Person's correlation was used to assess the degree of association between the two variables.RESULTS: VEGF levels and serum tryptase in HCC patients before TACE had a mean value and standard deviation (SD) of 114.31 +/- 79.58 pg/mL and 8.13 +/- 3.61 mu g/L, respectively. The mean levels and SD of VEGF levels and serum tryptase in HCC patients after TACE were 238.14 +/- 109.41 pg/mL and 4.02 +/- 3.03 mu g/L. The changes between the mean values of concentration of VEGF and tryptase before treatment and after treatment was statistically significant (P < 0.000231 and P < 0.00124, by Wilcoxon-Mann-Whitney respectively). A significant correlation between VEGF levels before and after TACE and between tryptase levels before and after TACE was demonstrated (r = 0.68, P = 0.003; r = 0.84, P = 0.000 respectively).CONCLUSION: Our pilot results suggest that the higher serum VEGF levels and the lower tryptase levels following TACE may be potential biomarkers changing in response to therapy.